284 related articles for article (PubMed ID: 26030803)
1. Computational Docking Study of p7 Ion Channel from HCV Genotype 3 and Genotype 4 and Its Interaction with Natural Compounds.
Mathew S; Fatima K; Fatmi MQ; Archunan G; Ilyas M; Begum N; Azhar E; Damanhouri G; Qadri I
PLoS One; 2015; 10(6):e0126510. PubMed ID: 26030803
[TBL] [Abstract][Full Text] [Related]
2. Molecular design, synthesis and biological evaluation of cage compound-based inhibitors of hepatitis C virus p7 ion channels.
Shiryaev VA; Radchenko EV; Palyulin VA; Zefirov NS; Bormotov NI; Serova OA; Shishkina LN; Baimuratov MR; Bormasheva KM; Gruzd YA; Ivleva EA; Leonova MV; Lukashenko AV; Osipov DV; Osyanin VA; Reznikov AN; Shadrikova VA; Sibiryakova AE; Tkachenko IM; Klimochkin YN
Eur J Med Chem; 2018 Oct; 158():214-235. PubMed ID: 30218908
[TBL] [Abstract][Full Text] [Related]
3. Understanding the inhibitory mechanism of BIT225 drug against p7 viroporin using computational study.
Behmard E; Abdolmaleki P; Taghdir M
Biophys Chem; 2018 Feb; 233():47-54. PubMed ID: 29169687
[TBL] [Abstract][Full Text] [Related]
4. Computational Study of HCV p7 Channel: Insight into a New Strategy for HCV Inhibitor Design.
Ying B; Pang S; Yang J; Zhong Y; Wang J
Interdiscip Sci; 2019 Jun; 11(2):292-299. PubMed ID: 30194627
[TBL] [Abstract][Full Text] [Related]
5. "Too little, too late?" Will inhibitors of the hepatitis C virus p7 ion channel ever be used in the clinic?
Griffin S
Future Med Chem; 2014; 6(17):1893-907. PubMed ID: 25495983
[TBL] [Abstract][Full Text] [Related]
6. Structure-guided design affirms inhibitors of hepatitis C virus p7 as a viable class of antivirals targeting virion release.
Foster TL; Thompson GS; Kalverda AP; Kankanala J; Bentham M; Wetherill LF; Thompson J; Barker AM; Clarke D; Noerenberg M; Pearson AR; Rowlands DJ; Homans SW; Harris M; Foster R; Griffin S
Hepatology; 2014 Feb; 59(2):408-22. PubMed ID: 24022996
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of HCV p7 as a therapeutic target.
Griffin S
Curr Opin Investig Drugs; 2010 Feb; 11(2):175-81. PubMed ID: 20112167
[TBL] [Abstract][Full Text] [Related]
8. Ion Channel Function and Cross-Species Determinants in Viral Assembly of Nonprimate Hepacivirus p7.
Walter S; Bollenbach A; Doerrbecker J; Pfaender S; Brown RJP; Vieyres G; Scott C; Foster R; Kumar A; Zitzmann N; Griffin S; Penin F; Pietschmann T; Steinmann E
J Virol; 2016 May; 90(10):5075-5089. PubMed ID: 26962224
[TBL] [Abstract][Full Text] [Related]
9. In depth analysis on the binding sites of adamantane derivatives in HCV (hepatitis C virus) p7 channel based on the NMR structure.
Du QS; Wang SQ; Chen D; Meng JZ; Huang RB
PLoS One; 2014; 9(4):e93613. PubMed ID: 24714586
[TBL] [Abstract][Full Text] [Related]
10. Investigation of viral escape mutations within HCV p7 during treatment with amantadine in patients with chronic hepatitis C.
Vermehren A; Welsch C; Elsler U; Vermehren J; Herrmann E; Sarrazin C; von Wagner M; Susser S; Hofmann WP; Kronenberger B; Zeuzem S; Mihm U
Antivir Ther; 2013; 18(6):803-11. PubMed ID: 23824381
[TBL] [Abstract][Full Text] [Related]
11. Genotype-dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel.
Griffin S; Stgelais C; Owsianka AM; Patel AH; Rowlands D; Harris M
Hepatology; 2008 Dec; 48(6):1779-90. PubMed ID: 18828153
[TBL] [Abstract][Full Text] [Related]
12. Cell viability assay as a tool to study activity and inhibition of hepatitis C p7 channels.
Breitinger U; Farag NS; Ali NKM; Ahmed M; El-Azizi MA; Breitinger HG
J Gen Virol; 2021 Mar; 102(3):. PubMed ID: 33709903
[TBL] [Abstract][Full Text] [Related]
13. Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus.
Steinmann E; Whitfield T; Kallis S; Dwek RA; Zitzmann N; Pietschmann T; Bartenschlager R
Hepatology; 2007 Aug; 46(2):330-8. PubMed ID: 17599777
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus p7: molecular function and importance in hepatitis C virus life cycle and potential antiviral target.
Khaliq S; Jahan S; Hassan S
Liver Int; 2011 May; 31(5):606-17. PubMed ID: 21457434
[TBL] [Abstract][Full Text] [Related]
15. The stability of secreted, acid-labile H77/JFH-1 hepatitis C virus (HCV) particles is altered by patient isolate genotype 1a p7 sequences.
Atkins E; Tatineni R; Li H; Gretch D; Harris M; Griffin S
Virology; 2014 Jan; 448():117-24. PubMed ID: 24314642
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
[TBL] [Abstract][Full Text] [Related]
17. A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.
Selvapatt N; Habibi MS; Brown A
J Med Virol; 2015 Oct; 87(10):1716-21. PubMed ID: 25914248
[TBL] [Abstract][Full Text] [Related]
18. Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus p7 ion channel.
Foster TL; Verow M; Wozniak AL; Bentham MJ; Thompson J; Atkins E; Weinman SA; Fishwick C; Foster R; Harris M; Griffin S
Hepatology; 2011 Jul; 54(1):79-90. PubMed ID: 21520195
[TBL] [Abstract][Full Text] [Related]
19. Determinants of hepatitis C virus p7 ion channel function and drug sensitivity identified in vitro.
StGelais C; Foster TL; Verow M; Atkins E; Fishwick CW; Rowlands D; Harris M; Griffin S
J Virol; 2009 Aug; 83(16):7970-81. PubMed ID: 19493992
[TBL] [Abstract][Full Text] [Related]
20. Interaction of antivirals with a heptameric bundle model of the p7 protein of hepatitis C virus.
Dahl SL; Kalita MM; Fischer WB
Chem Biol Drug Des; 2018 Apr; 91(4):942-950. PubMed ID: 29251816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
